Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Initiated a new core position. An integrated payments...
— Adam Wilk
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Shift4 Payments, Inc.
We first discussed Shift4 in our Q1 letter, where we bought shares and then sold almost immediately after a more comprehensive analysis. Shift4 is a...
Despite missing consensus estimates, Shift4 showcased strong underlying metrics with 25% payment volume growth and 55% adjusted free cash flow growth. The manager remains...
The payment processor's stock fell after forward profit guidance fell below investor expectations. The manager retains...
More institutional theses from Greystone Capital
With that as a backdrop, KITS Eyecare recently announced that Co-Founder and COO, Joe Thompson would be stepping down from his current role and transitioning into an advisory role, effective immediately. It’s still early,...
During Q2 and into Q3, we built a position in Strata Critical Medical, an organ transplant and logistics business that has been left for dead given its microcap status, prior history as a failed SPAC, strategy shift and shareholder turnover. Strata has carved...
In addition, Strata is an equipment agnostic operator, meaning they can and will use whatever device or method is best for their customer when transporting organs, versus a business like Transmedics that relies on selling a proprietary device that customers have to use to ship each organ. Today, more and...